Drugs / LVsh5/C46 (Cal-1) transduced CD34+ HSPC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02378922 | Jun 2016 → Jun 2019 | HIV infectious disease, Hodgkins lymphoma, non-Hodgkin lymphoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LVsh5/C46 (Cal-1) transduced CD34+ HSPC | “Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV” NCT02378922 ↗ |